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Abstract
Purpose: The purpose of the current study was to evaluate the impact of spot
size on the interplay effect, plan robustness, and dose to the organs at risk for
lung cancer plans in pencil beam scanning (PBS) proton therapy
Methods: The current retrospective study included 13 lung cancer patients. For
each patient, small spot (∼3 mm) plans and large spot (∼8 mm) plans were
generated. The Monte Carlo algorithm was used for both robust plan optimization and final dose calculations. Each plan was normalized, such that 99% of
the clinical target volume (CTV) received 99% of the prescription dose. Interplay effect was evaluated for treatment delivery starting in two different breathing phases (T0 and T50). Plan robustness was investigated for 12 perturbed
scenarios, which combined the isocenter shift and range uncertainty. The nominal and worst-case scenario (WCS) results were recorded for each treatment
plan. Equivalent uniform dose (EUD) and normal tissue complication probability
(NTCP) were evaluated for the total lung, heart, and esophagus.
Results: In comparison to large spot plans, the WCS values of small spot plans
at CTV D95% , D96% , D97% , D98% , and D99% were higher with the average differences of 2.2% (range, 0.3%–3.7%), 2.3% (range, 0.5%–4.0%), 2.6% (range,
0.6%–4.4%), 2.7% (range, 0.9%–5.2%), and 2.7% (range, 0.3%–6.0%), respectively. The nominal and WCS mean dose and EUD for the esophagus, heart, and
total lung were higher in large spot plans. The difference in NTCP between large
spot and small spot plans was up to 1.9% for the total lung, up to 0.3% for the
heart, and up to 32.8% for the esophagus. For robustness acceptance criteria
of CTV D95% ≥ 98% of the prescription dose, seven small spot plans had all 12
perturbed scenarios meeting the criteria, whereas, for 13 large spot plans, there
were ≥2 scenarios failing to meet the criteria. Interplay results showed that, on
average, the target coverage in large spot plans was higher by 1.5% and 0.4%
in non-volumetric and volumetric repainting plans, respectively.
Conclusion: For robustly optimized PBS lung cancer plans in our study, a small
spot machine resulted in a more robust CTV against the setup and range errors
when compared to a large spot machine.In the absence of volumetric repainting,
large spot PBS lung plans were more robust against the interplay effect. The use
of a volumetric repainting technique in both small and large spot PBS lung plans
led to comparable interplay target coverage.
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INTRODUCTION

Pencil beam scanning (PBS) proton therapy has shown
great potential in reducing the dose to the organs at
risk (OARs) and improving dose conformality when compared to passive-scattering proton therapy.1 However,
uncertainties such as patient setup, beam range, and
the interplay between tumor motion and proton beam
delivery can have an impact on PBS treatment plans.2
Recently, robust optimization has been implemented
within treatment planning systems (TPS) to compensate
both setup and range uncertainties.3,4 Robustly optimized plans are evaluated in terms of plan robustness
by simulating the range uncertainty due to the computed
tomography (CT) calibration error and isocenter shift of
the patient due to inter-fraction variations in the patient’s
position.5
The spot size of a pencil proton beam can influence the plan quality and robustness in PBS proton
therapy.6–10 Plan robustness becomes more critical for
the PBS proton lung cancer treatment because the proton beam needs to transverse low- and high-density
interfaces in its path,and lung tumor volume may contain
large density variations. The evaluation of plan robustness for PBS proton treatment is equally important.11
Robust optimization can take into account the combination of setup and range errors and minimize the impact
of these errors on the clinical target volume (CTV) coverage and dose to the OARs.12,13 The literature addressing the impact of spot size on the plan robustness (setup
and range errors) for PBS lung cancer is limited. Liu
et al.9 investigated the effect of spot size on plan robustness for PBS lung plans and reported that results were
similar in a small spot and large spot plans. However, Liu
et al.9 evaluated the setup and range uncertainties separately, whereas, in a real clinical situation, it is possible
that setup errors can occur in conjunction with the range
error.
Early investigators have compared small versus large
spot sizes to mitigate the interplay effect. Liu et al.9
demonstrated that small spot and large spot machines
produced comparable interplay effects in 10 lung cancer patients. By contrast, Grassberger et al.7 showed
that large spot plans are more robust to motion effects
due to reduced interplay effect when compared to the
small spot plans. In a different study by Grassberger
et al.,14 it was shown that large spot size plans needed
two repaintings (either layer or volumetric) to restore
the dose, whereas small spot size plans needed 2
to 6 repaintings to mitigate the interplay effect. Liu
et al.9 used a synchrotron-based spot scanning system
(Hitachi ProBeat; Hitachi Ltd, Tokyo, Japan), whereas
the study by Grassberger et al.7 was based on the earlier version of the IBA machine at Massachusetts General Hospital. One of the differences between these

two studies was that Grassberger et al.7,14 used a nonrobust optimization technique for treatment planning,
whereas Liu et al.9 generated all plans using a robust
optimization technique.
Recently, volumetric repainting technique in an alternating order has been made available on the ProteusPLUS IBA proton machines with a dedicated PBS
nozzle.15 The use of repainting techniques such as
layer and volumetric can reduce the interplay effect by
averaging out of hot and cold spots.16 The alternating order in volumetric repainting allows beam delivery sequences in “down” and “up” directions – which
means the beam can be delivered from the highest
energy layer to the lowest energy layer as well as from
the lowest energy layer to the highest energy layer. A
faster energy layer switching in the “down” and “up”
directions is achieved by using a magnetic field regulation feature. In previous studies,15,17 experiments were
performed investigating the impact of magnetic field
regulation in conjunction with the volumetric repainting
technique on the spot size, spot position, and range in
PBS proton therapy. In a separate publication,18 a small
spot size beam model was used to investigate the volumetric repainting technique in mitigating the interplay
effect for 4D robustly optimized PBS proton lung plans.
However, the impact of large spot size on plan robustness and interplay effect was not addressed in that
study.18
In recent years, new proton therapy centers are
equipped with a small spot size. Proton therapy vendors
may also provide an additional option for the large spot
size on the same machine. This leads to the questions
– Is it worth purchasing a PBS proton machine that can
provide both small and large spot sizes? How can we utilize small and large spot sizes for the volumetric repainting technique in an alternating order? It is important to
understand if there are any dosimetric and radiobiological benefits in using a small spot size versus a large spot
size in PBS proton therapy.
The primary aim of the current study was therefore to
answer the following questions:
1. What is the impact of spot size on the interplay effect
in lung cancer if a proton beam is delivered using
a volumetric repainting technique in an alternating
order?
2. What is the dosimetric impact of spot size on plan
robustness for lung cancer? For plan robustness, the
setup error is combined with the range error, whereas
the previous study9 evaluated the setup and range
errors separately.
3. How does the combination of range and setup errors
affects the equivalent uniform dose (EUD) and normal tissue complication probability (NTCP) for the
OARs in lung cancer?
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TA B L E 1

3

The location of clinical target volume (CTV) and its motion and volume in 13 lung cancer patients

Patient
#

CTV
(cc)

1

174.6

2

103.9

Motion
(mm)

Location

Mediastinum
involvement

2.7

RL

Yes

4.7

LUL

No

3

36.5

7.2

RUL

No

4

181.0

13.2

RLL

No

5

24.4

4.8

LUL

No

6

34.2

5.8

LLL

No

7

23.2

4.2

RL

No

8

22.1

8.8

RLL

No

9

26.0

10.1

RLL

No

10

39.3

10.2

RLL

No

11

366.3

2.5

LL

Yes

12

186.8

2.2

RL

Yes

13

26.5

8.1

RLL

No

Abbreviations: LL, left lung; LLL, left lower lobe; LUL, left upper lobe; RL, right lung; RLL, right lower lobe; RUL, right upper lobe.

2
2.1

MATERIAL AND METHODS
Contouring and treatment planning

In this Institutional Review Board-approved retrospective dosimetric study, a total of 13 lung cancer patients
were selected. Table 1 shows the location of CTV
and their motions and volumes in the 13 lung cancer
patients. The selection criteria included the presence
of four-dimensional CT (4DCT) scans of ten breathing phases and the lung tumor motion of less than
15 mm. The mediastinum involvement in the target volume was allowed. The 4DCT data set of each patient
was anonymized. The tumor motion range ranged from
2.2 to 13.2 mm. The CTV was generated by an isotropic
margin of 5 mm around the internal gross tumor volume (IGTV). The IGTV is then overridden with the density of the water.1 The average intensity projection CT
was used for treatment planning. Treatment plans were
generated in RayStation TPS (clinical version 9B; RaySearch Laboratories, Stockholm, Sweden) based on a
single field uniform dose (SFUD) technique for a total
dose of 70 Gy(RBE) with a fractional dose of 2 Gy(RBE)
using an average RBE of 1.1. For a given patient, treatment planning was performed in three steps.
First, a small spot beam model (1σ = 3 mm at isocenter for energy 226.5 MeV) was used to generate small
spot plans with no repainting (SSNR). This model is
based on the IBA ProteusPLUS proton therapy system with a dedicated PBS nozzle.19 For each patient,
the optimal beam angles were selected based on the
location of the CTV and OARs. The number of beams
in a treatment plan varied from 2–3. Treatment plans
were robustly optimized (Monte Carlo; 10 000 ions/spot;
SFUD technique) on the CTV using 5 mm setup
uncertainty and 3.5% range uncertainty3 with a goal

of 99% of the CTV receiving at least 99% of the prescription dose. Once the final dose calculations (Monte
Carlo; 0.5% statistical uncertainty; 3 mm grid size) were
completed,SSNR plans were normalized,such that CTV
D99% = 6930 cGy(RBE).
Second, a large spot beam model (1σ = 8 mm at
isocenter for energy 226.5 MeV) was used to generate large spot plans with no repainting (LSNR). Spot
profiles in a large spot beam model were generated by
scaling the spot profiles from a small spot beam model
(Figure 1) Other beam model components such as
absolute dose output and integrated depth doses (IDDs)
remained identical in large spot and small spot beam
models. For a given patient, an SSNR plan was copied
and switched to a large spot beam model. The plan was
then robustly re-optimized using the same settings like
the ones in small spot plan optimization. Also, the number of treatment fields, optimization settings, and optimization objectives remained identical in large spot and
small spot plans. To be consistent with SSNR plans, all
LSNR plans were calculated with Monte Carlo (0.5%
statistical uncertainty; 3 mm grid size) and normalized,
such that 99% of the CTV received 6930 cGy(RBE).
Third, for a given patient, an SSNR was used to generate a volumetric repainting plan with five continuous
paintings in an alternating order15 (hereafter referred to
as SSVR plans). Dose distributions in nominal SSNR
and SSVR plans were identical. Figure 2 shows the
schematic of the volumetric repainting technique in an
alternating order. Similarly, an LSNR plan was used to
generate a volumetric repainting plan with five paintings in an alternating order (hereafter referred to as
LSVR plans). It was verified there was no change in the
dose distributions when generating an LSVR plan from
the LSNR plan. In order to ensure the deliverability of
spots on the machine, a minimum monitor unit (MU) of

4
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F I G U R E 1 Example of spot profiles from
the small spot and large spot models at the
isocenter for 100, 150, and 225 MeV

5. Heart: Dmean
6. Esophagus: Dmean
7. Spinal Cord: D0.03cc
The difference (Δ) between SSVR and LSVR plans
was calculated using Equation (1).
)
(
Δ Dx = DLSVR
− DSSVR
x
x

F I G U R E 2 Beam delivery directions in a volumetric repainting
plan with an alternating order; Note: beam delivery starts from the
distal energy layer to the proximal energy layer, and then follows an
alternating order. All plans in the current study included five
repaintings

0.015 was applied to all SSVR and LSVR plans. All volumetric repainting plans were generated based on the
methodology described by Engwall et al.12,13 Prior to
dose computation for robustness testing, both sets of
plans (SSVR and LSVR) were verified, such that CTV
D99% = 6930 cGy(RBE).

2.2

Robustness analysis

Plan robustness was investigated for 12 perturbed scenarios, which combined the isocenter shift and range
uncertainty. The isocenter of the patient was shifted by
5 mm in the superior-inferior,anterior-posterior,and rightleft directions, whereas ±3.5% was used for the range
uncertainty. The following metrics were used to evaluate the worst-case scenario (WCS) values based on 12
perturbed scenarios.
1.
2.
3.
4.

CTV: D95% , D96% , D97% , D98% , and D99% .
CTV: D0.03cc
CTV Homogeneity Index (HI): D99% /D1%
Total lung: Dmean , V20 , and V5 (note: total lung
includes both lungs except CTV)

(1)

where, Dx = dosimetric metric (e.g., Dmean , V20 , etc.);
= dosimetric result of Dx in LSVR plan;
DLSVR
x
=
dosimetric result of Dx in SSVR plan;
DSSVR
x

2.3

Radiobiological analysis

EUD and NTCP evaluation was performed using the
dose-volume histograms (DVHs) of the SSVR and
LSVR plans. EUD is based on Niemierko’s phenomenological model.20,21 To estimate the clinical outcomes of the SSVR and LSVR plans, the EUDbased NTCP20,21 was calculated for all perturbed scenarios. The Total lung, heart, and esophagus were
evaluated for the endpoints of pneumonitis, pericarditis, and esophagitis, respectively.20,21 The difference
(Δ) in radiobiological results was evaluated using
Equation (1).
(
EUD =

)1
) a
∑(
a
vi EQDi

(2)

i=1

⎞
⎟
⎟
⎟
⎠

(3)

)4𝛾50

(4)

⎛𝛼 + D
⎜ 𝛽 nf
EQD = D × ⎜ 𝛼
⎜ 𝛽 +2
⎝
NTCP =
1+

(

1
TD50
EUD

RANA AND ROSENFELD

where a = unit-less model parameter that is specific to
the normal structure or tumor of interest
vi = unit-less ith partial volume receiving dose Di in Gy
EQD = biologically equivalent physical dose of 2 Gy
nf = number of fractions
df = D/nf = dose per fraction size of the treatment
course
TD50 = tolerance dose for a 50% complication rate at
a specific time interval when the whole organ of interest
is homogeneously irradiated
γ50 = unit-less model parameter that is specific to the
normal tissue of interest and describes the slope of the
dose-response curve
The values of a,γ50 ,and TD50 for OARs were obtained
from the published literature.22–24

2.4

Interplay effect analysis

The interplay effect was studied in RayStation TPS (clinical version 9B) using the methodology described by

5

Engwall et al.12,13 First, deformable registration was performed between the average intensity projection CT
and breathing phases from the 4DCT data set using
ANAtomically CONstrained Deformation Algorithm.12
For the interplay effect analysis, we used the energy
layer switching time of 1 s and spot delivery time of
4.0 ms/MU. The motion speed between spots was set to
250 cm/s. The analysis was performed with an assumption of treatment delivery starting in two phases: 0%
representing end-inhalation (T0 ) and 50% representing end-exhalation (T50 ). The spots in a treatment plan
were distributed over 10 breathing phases according to
starting phase (T0 and T50 ) for the beam delivery and
spot timings as mentioned above. The dose was computed on ten different breathing phases based on the
spot distribution.12,13 This was followed by mapping of
the dose to the reference phase through deformable
registration.12,13 The final step included the accumulation of the mapped doses on the reference phase.12,13
The interplay DVHs were utilized to evaluate CTV D95% ,
D99% , and HI.

F I G U R E 3 (a) The worst-case scenario (WCS) values in the large spot plans with five volumetric repaintings (LSVR) and small spot plans
with five volumetric repaintings (SSVR) at different dosimetric metrics; (b) Number of perturbed scenarios passing meeting the robustness
criteria in LSVR and SSVR plans; (c) Nominal homogeneity index (HI) in LSVR and SSVR plans; and (d) WCS HI in LSVR and SSVR plans

6
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F I G U R E 4 (a,b) Nominal dose
distributions in large spot and small spot plans
with and without volumetric repainting
technique in an example patient; (c,d)
Interplay dose distributions without volumetric
repainting in large spot and small spot plans in
the same patient; (e,f) Interplay dose
distributions with volumetric repainting in large
spot and small spot plans in the same patient.
Note: Red contour = CTV, Blue = 6930
cGy(RBE), yellow = 6650 cGy(RBE);
green = 3000 cGy(RBE); LSNR = large spot
plan with no volumetric repainting,
SSNR = small spot plan with no volumetric
repainting, LSVR = large spot plan with five
volumetric repaintings, SSVR = small spot
plan with five volumetric repaintings

3
3.1
3.1.1

RESULTS

The WCS HI was 0.91 and 0.88 in SSVR and LSVR,
respectively.

Target volume
Plan robustness

Figure 3a shows the WCS results of the CTV D95% ,
D96% , D97% , D98% , and D99% . For a given dosimetric
metric, the WCS result in the SSVR plan (denoted by
a circle in Figure 3a) was higher than in the LSVR
plan (denoted by a star in Figure 3a), thus clearly
indicating that SSVR plans were more robust than
LSVR plans. Specifically, on average, the WCS values at
D95% , D96% , D97% , D98% , and D99% were higher by 2.2%
(range, 0.3%–3.7%), 2.3% (range, 0.5%–4.0%), 2.6%
(range, 0.6%–4.4%), 2.7% (range, 0.9%–5.2%), and
2.7% (range, 0.3%–6.0%), respectively. For robustness
acceptance criteria of D95% ≥ 6860 cGy(RBE), seven
SSVR plans had all 12 perturbed scenarios meeting
the criteria, whereas, for 13 LSVR plans, more than
two scenarios were failing to meet the criteria. For
treatment plans failing to meet the robustness criteria
for all scenarios (Figure 3b), the number of scenarios
that met the criteria ranged from 9 to 11 in SSVR plans
(n = 6) and from 6 to 10 in LSVR plans (n = 13). Hot
spot evaluation showed that the average difference in
WCS values of D0.03cc was lower in SSVR plans by 0.4
± 1.4%. Figure 3c,d shows the nominal HI and WCS HI
of perturbed scenarios, respectively, for all 13 patients.
For both nominal and perturbed scenarios, small spot
plans produced more homogenous dose distributions
compared to large spot plans. Specifically, for a nominal
scenario, dose homogeneity was superior in SSVR
plans (HI = 0.97) than in LSVR plans (HI = 0.95). A
similar trend was observed for the perturbed scenarios.

3.1.2

Interplay effect

Figure 4 illustrates an example of nominal and interplay dose distributions in the small spot and large spot
plans with and without volumetric repainting technique.
Figure 5 provides the difference in CTV D95% and D99%
from interplay DVHs between small spot and large spot
plans. In the absence of volumetric repainting, large spot
plans were found to be more robust to interplay effect
when compared to small spot plans. Specifically, the
average differences in D95% and D99% between LSNR
and SSNR plans were 1.2 ± 1.0% and 1.3 ± 1.4%,
respectively. Figure 4c,d illustrates the interplay of dose
distributions in LSNR and SSNR plans, respectively. The
loss of CTV D99% (blue color) is clearly visible in interplay SSNR dose distribution as shown in Figure 4d.
However, after utilizing the volumetric repainting technique in both sets of plans, the interplay dose distributions between small and large spot plans were found
to be comparable. The average differences in D95% and
D99% between LSVR and SSVR plans were 0.4 ± 0.6%
and 0.4 ± 0.8%, respectively. Figure 4f illustrates that the
target coverage loss was recovered in interplay SSVR
dose distribution after applying five volumetric repaintings. Figure 5 shows the summary of HI results from
interplay DVHs of small spot and large spot plans. If
no volumetric repainting technique was used, the HI in
LSNR was slightly better than in SSNR plans (0.94 ±
0.02 vs. 0.92 ± 0.03). The use of the volumetric repainting technique resulted in similar HI results in LSVR (0.95
± 0.01) and SSVR (0.96 ± 0.01) plans.
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TA B L E 2 Equivalent uniform dose (EUD) and normal tissue
complication probability (NTCP) for the total lung, heart, and
esophagus in spot plan with five volumetric repaintings (LSVR) and
small spot plan with five volumetric repaintings (SSVR)
Total lung
Patient #

EUD (cGy(RBE))
SSVR
LSVR

NTCP (%)
SSVR
LSVR

1

636

1128

492

0.00

0.10

0.10

2

708

931

223

0.00

0.02

0.02

3

497

1064

566

0.00

0.06

0.06

4

548

1087

540

0.00

0.07

0.07

5

259

600

341

0.00

0.00

0.00

6

407

806

400

0.00

0.01

0.01

Δ

Δ

7

99

281

181

0.00

0.00

0.00

8

484

1117

633

0.00

0.09

0.09

9

431

728

296

0.00

0.00

0.00

10

671

1359

688

0.00

0.44

0.43

11

752

1262

510

0.00

0.24

0.24

12

977

1641

664

0.03

1.94

1.91

13

426

990

564

0.00

0.03

0.03

Δ

NTCP (%)
SSVR
LSVR

Δ
0.20

Heart
Patient #

EUD (cGy(RBE))
SSVR
LSVR

1

2200

2866

666

0.01

0.20

2

49

331

282

0.00

0.00

0.00

3

1831

2644

813

0.00

0.08

0.08

4

1953

2705

752

0.00

0.10

0.10

5

4

229

225

0.00

0.00

0.00

6

658

1508

850

0.00

0.00

0.00

7

0

7

7

0.00

0.00

0.00

8

1097

1441

344

0.00

0.00

0.00

9

250

414

164

0.00

0.00

0.00

10

681

1041

361

0.00

0.00

0.00

11

32

631

599

0.00

0.00

0.00

12

2356

3003

647

0.02

0.36

0.34

13

1655

2386

731

0.00

0.02

0.02

Δ

NTCP (%)
SSVR
LSVR

Δ

12.57

29.34

Esophagus

F I G U R E 5 Difference in clinical target volume (CTV) D95% ,
D99% , and homogeneity index (HI) from interplay dose-volume
histograms (DVHs) between small spot and large spot plans

Patient #

EUD (cGy(RBE))
SSVR
LSVR

1

4002

4896

2

981

1520

538

0.00

0.01

0.01

3

3

137

133

0.00

0.00

0.00

4

1779

3266

1487

0.02

2.75

2.73

5

387

629

242

0.00

0.00

0.00

6

463

1503

1040

0.00

0.01

0.01

7

3184

3722

538

2.25

7.44

5.19

8

0

34

34

0.00

0.00

0.00

9

894

41.91

0

0

0

0.00

0.00

0.00

10

535

597

63

0.00

0.00

0.00

11

4399

4870

471

23.45

40.87

17.42

12

3529

4792

1263

5.00

37.79

32.80

13

198

738

540

0.00

0.00

0.00
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F I G U R E 6 (a) Difference in D0.03cc of nominal results for the spinal cord between large spot plans with five volumetric repaintings (LSVR)
and small spot plans with five volumetric repaintings (SSVR); (b) Difference in D0.03cc of worst-case scenario (WCS) results for the spinal cord
between LSVR and SSVR plans; (c) Difference in Dmean of nominal results for the organs at risk (OARs; esophagus, heart, and total lung)
between LSVR and SSVR plans; (d) Difference in Dmean of WCS results for the OARs (esophagus, heart, and total lung) between LSVR and
SSVR plans; (e) Difference in V20 and V5 of nominal results for the total lung between LSVR ad SSVR plans; (f) Difference in V20 and V5 of
WCS results for the total lung between LSVR ad SSVR plans

RANA AND ROSENFELD
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F I G U R E 7 Equivalent uniform dose (EUD) of the total lung for 12 perturbed scenarios (S1–S12) in large spot plans with five volumetric
repaintings (LSVR) and small spot plans with five volumetric repaintings (SSVR) of all 13 patients

3.2

Organs at risk

Figure 6a shows the difference in D0.03cc to the spinal
cord in nominal plans. The difference in WCS D0.03cc to
the spinal cord is presented in Figure 6b. For a nominal
scenario, a large spot beam model resulted in a higher
D0.03cc by an average difference of 1570 cGy(RBE). A
similar observation was made for the WCS D0.03cc to
the spinal cord (Δ = 1562 cGy[RBE]). Both the nominal
and WCS Dmean to the esophagus, heart, and total lung
was higher in LSVR plans. (Figures 6c,d) Specifically,
for a nominal scenario, the average difference for the
esophagus,heart,and total lung was 576 cGy(RBE),212
cGy(RBE), and 505 cGy(RBE), respectively, whereas the
difference in WCS values from the perturbed scenarios
was 572 cGy(RBE), 258 cGy(RBE), and 549 cGy(RBE),
respectively. The average difference in V20 and V5 of the
total lung for a nominal scenario was 8.3% and 12.0%,
respectively. (Figure 6e) A similar difference was found
for the WCS V20 (Δ = 8.9%) and V5 (12.4%) of the total
lung. (Figure 6f )
Table 2 provides the WCS results of EUD and NTCP
for the total lung, heart, and esophagus. Figure 7 shows
the total lung EUD for 12 perturbed scenarios in all 13
patients. On average, the difference in EUD was 469
cGy(RBE) for the total lung, 495 cGy(RBE) for the heart,
and 557 cGy(RBE) for the esophagus. For the NTCP, the
difference ranged from 0% to 1.91% for the total lung,
from 0% to 0.34% for the heart, and from 0% to 32.80%
for the esophagus.

4

DISCUSSION

The current study was performed to determine if there
is a dosimetric and radiobiological benefit of using

small spot size versus large spot size for lung plans
in PBS proton therapy. All treatment plans in our study
were robustly optimized against the setup and range
uncertainties. Also, we assumed that range uncertainties occurred in conjunction with an isocentric shift of
the patient in a given direction (superior-inferior, anteriorposterior, and right-left), thus resulting in 12 perturbed
scenarios. In order to make a fair plan comparison, both
sets of plans (SSVR and LSVR) were normalized, such
that CTV D99% = 6930 cGy(RBE). The WCS results at
various dosimetric metrics of the CTV showed that the
target coverage in LSVR plans was reduced by up to 6%.
In comparison to LSVR plans, the number of scenarios
passing the robustness criteria (D95% ≥ 6860 cGy[RBE])
in each patient was higher in SSVR plans, except for
patients #8 and #12 – both plans (SSVR and LSVR)
produced the same number of scenarios passing the
criteria for these two patients.
Recently, new proton centers are installing machines
with smaller spot sizes. Plan robustness results from our
study demonstrated that if a lung plan is robustly optimized with a small spot beam model (∼3 mm) and volumetric repainting is applied, it is feasible to generate
a treatment plan that is robust against the setup and
range errors. However, if an SSVR plan requires the use
of a range shifter in the beam path, this will create an
air gap between the downstream of a range shifter and
patient body/immobilization devices. Since in-air spot
size increases with an increase in the air gap,25–27 it
is recommended to minimize the air gap between the
range shifter and patient. This will allow maintaining the
robustness of the target volume against the setup and
range errors as well as decrease the EUD for the OARs.
The OARs results from our study showed that the
smaller spot model produced a lower dose to the normal total lung, heart, esophagus, and spinal cord. These
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findings are in agreement with Liu et al.9 We also noticed
that the small spot model resulted in a decrease in EUD
for the total lung, heart, and esophagus. The NTCPs for
the total lung and heart were found to be comparable
in both sets of plans, whereas the difference in NTCP
of esophagus between large spot and small spot plans
was found to vary from 0% to 32.8%. Such a large difference in NTCP of the esophagus between two sets of
plans can be attributed to the location of tumor volume.
In patients #1 (ΔNTCP = 29.3%),#11 (ΔNTCP = 17.4%),
and #12 (ΔNTCP = 32.8%), the mediastinum is included
in the CTV. The location of the CTV in the proximity of
the esophagus and wider penumbrae from large spots
were found to be contributing factors for increased EUD
and NTCP of the esophagus in large spot plans of
patients #1, #11, and #12. The NTCP results presented
in our study include the uncertainty in the calculations.
The NTCP calculations included the parameters that are
derived from the photon therapy. Proton-specific radiobiological parameters for lung cancer are needed to obtain
more accurate NTCP calculations, which can be correlated to the tissue toxicities.
Although our study was undertaken on the lung
disease site, it is relevant to mention plan robustness
studies conducted on other disease sites. For instance,
Moteabbed et al.10 investigated the impact of spot size
on 14 patients (seven central nervous system [CNS],
four head and neck, two pelvic, and one thoracic solid
tumors) and concluded that plan quality improved as the
spot size decreased. More recently, Kraan et al.8 investigated the impact of spot size on plan robustness in
seven patients of different cancer sites (pelvis, chest
wall, rectum, chordoma, cardiac, retroperitoneal, and sarcoma). The results from Kraan et al.8 showed that small
spot plans are more robust against spot size changes
than large spot plans.
Treatment of lung cancer using PBS protons can
raise the concern of the interplay effect between
tumor motion and delivery of pencil proton beams. The
interplay effect evaluation from our study provided two
major observations. First, if PBS lung plans with motion
did not include the volumetric repainting, small spot
plans were found to be more sensitive to the interplay
compared to large spot plans. A similar observation was
reported by Grassberger et al.7 in their PBS lung cancer study (no repainting strategies utilized). The repainting techniques were applied by Grassberger et al.14 in
a separate study with focus on the layer and volumetric repainting techniques. It was demonstrated that the
number of repaintings needed in large spot plans was
lower than in small spot plans. The robust optimization technique was not applied in their study.14 Our second observation was that, after applying five volumetric
repaintings,the interplay effect in SSVR and LSVR plans
was found to be comparable. Liu et al.9 also reported
the comparable interplay effect results for small spot
and large spot plans using layer repainting strategies.
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In the current study, we applied a total of five volumetric repaintings across all patients. For a given treatment field in a patient, the beam-on time and number
of energy layers in a small spot versus a large spot
plan were found to be similar. Overall, for five volumetric repaintings, beam-on time per treatment field ranged
from 72 to 216 s, whereas the energy layers ranged from
65 to 165. The number of volumetric repaintings needed
to reduce the interplay effect could vary from one patient
to another.13,18 The readers must not assume that five
repaintings used in the current study are an ideal number for the volumetric repainting technique in PBS lung
cancer plans. Instead, patient-specific interplay effect
evaluation is recommended to determine the optimal
number of repaintings.13,18

5

CONCLUSION

For robustly optimized PBS lung cancer plans in our
study, a small spot machine resulted in a more robust
CTV against the setup and range errors when compared
to a large spot machine. Overall, small spot plans produced lower EUD for the OARs. In the absence of volumetric repainting technique, large spot PBS lung plans
were more robust against the interplay effect. However, the use of a volumetric repainting technique in
an alternating order in both small and large spot PBS
lung cancer plans led to comparable interplay target
coverage.
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